Breakthroughs with NASH Management: What Do Gastroenterologists and Hepatologists Need to Know?

Non-alcoholic steatohepatitis (NASH), an advanced form of non-alcoholic fatty liver disease (NAFLD), is a severe liver disorder with a rapidly progressive course that can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma. In order to prevent irreversible liver damage, patients with NASH should receive immediate treatment. However, distinguishing NASH from other liver disorders and identifying high-risk patients remain challenges, and there are limited treatment options once a patient is diagnosed. While there are no approved medical therapies for NASH, multiple investigational agents have shown promise in late-stage trials and are expected to be available for NASH treatment soon.

This activity, Breakthroughs with NASH Management: What Do Gastroenterologists and Hepatologists Need to Know? will provide clinicians with the most current guidance on NASH diagnostic strategies. Clinician learners will also receive information on the efficacy, safety, and potential use of novel agents in late-stage clinical investigation for the treatment of patients with NASH.

Welcome and Introduction
Understanding Optimal Evaluation of Patients with NASH
Staying Up-To-Date with the Latest NASH Advances
Q&A Session

The intended audiences for this educational initiative are hepatologists and gastroenterologists involved in the assessment and management of adults with NASH.

This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.

At the conclusion of this activity, participants should be able to:

• Implement guideline- and expert-recommended strategies to diagnose NASH and evaluate its severity
• Evaluate the safety and efficacy data for the NASH therapies in late-stage development

This activity is for informational purposes only.

This activity is for informational purposes only.

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

The contents of some activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an internet browser capable of playing a video.

Jointly provided by Penn State College of Medicine and Rockpointe

 

This program is supported by educational grant from Intercept Pharmaceuticals, Inc.